Reexploring cytomegalovirus serology in allogeneic hematopoietic cell transplantation
Page 1 QCO 370412 CURRENT OPINION Reexploring cytomegalovirus serology in …

B. George, N. Pati, N. Gilroy, M. Ratnamohan, G. Huang, I. Kerridge, M. Hertzberg, D.
Gottlieb, K. Bradstock. Pre‐transplant cytomegalovirus (CMV) serostatus remains the most …

Cytomegalovirus (CMV) reactivation occurs in up to 60% of CMV‐seropositive recipients
after allogeneic hematopoietic stem cell transplantation (HSCT). The incidence of CMV …

The role of cytomegalovirus serostatus on outcome of hematop... : Current Opinion in
Hematology The role of cytomegalovirus serostatus on outcome of hematopoietic stem cell …

Cytomegalovirus (CMV) reactivation remains one of the main infectious complications
following hematopoietic stem cell transplantation (HSCT). In this study, we explored the role …

We conducted a single‐center retrospective review of patients who had received allogeneic
hematopoietic stem cell transplantation (HSCT) between January 2003 and December …

Background Cytomegalovirus‐specific T‐cell‐mediated immunity (CMV‐CMI) protects from
CMV infection in allogeneic hematopoietic cell transplantation (allo‐HCT), but to date, there …

Background Allogeneic hematopoietic cell transplant recipients (allo-HCTRs) with positive
cytomegalovirus (CMV) serology may have false-positive results due to blood product …

Cytomegalovirus (CMV) reactivation post‐allogeneic hematopoietic cell transplantation
(post‐alloHCT) increases morbidity and mortality. We sought to determine the frequency of …

Despite the refinements in molecular methods for the detection of cytomegalovirus (CMV)
and the advent of highly effective preemptive strategies, CMV remains a leading cause of …